

**MEDICARE PRESCRIPTION DRUG AND IMPROVEMENT ACT  
REQUIRES DRUG COMPANIES TO FILE CERTAIN AGREEMENTS  
WITH THE FEDERAL TRADE COMMISSION AND U.S. DEPARTMENT OF JUSTICE**

*Effective Date of the Act's Filing Requirements: Wednesday, January 7, 2004.*

Section 1112 of Subtitle B ("Federal Trade Commission Review") of Title XI of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (the Act) requires that brand-name drug manufacturers and generic drug applicants file certain agreements with the Federal Trade Commission and the Assistant Attorney General (the Antitrust Agencies) within 10 business days of execution of the agreement. This requirement covers agreements executed on or after January 7, 2004.

The Antitrust Agencies will track the filing of these agreements and may, in the future, propose rules as necessary and appropriate to carry out the purposes of this subtitle.

*Agreements That Must be Filed*

Section 1112 identifies the two categories of agreements that if executed on or after January 7, 2004, are to be filed with the Antitrust Agencies.

1. Section 1112(a) Generic-Brand Agreements: Section 1112(a) requires a generic drug applicant that has submitted an Abbreviated New Drug Application (ANDA) containing a certification under Section 505 (j)(2)(A)(vii)(IV) of the Federal Food, Drug, and Cosmetic Act (FFDCA) and a brand name company<sup>1</sup> that enter into an agreement regarding
  - (A) the manufacture, marketing, or sale of a brand name drug that is listed in the ANDA involved;
  - (B) the manufacture, marketing, or sale of the generic drug for which the ANDA was submitted; or
  - (C) the 180-day period referred to in Section 505(j)(5)(B)(iv) of the FFDCA as it applies to such ANDA or to any other ANDA based on the same brand name drug

to file the agreement with the Antitrust Agencies, subject to the requirement of Section 1112(c). Section 1112(a)(1) provides that "[t]he agreement shall be filed prior to the date of the first commercial marketing of the generic drug that is the subject of the ANDA."

---

<sup>1</sup> Section 1111(4) defines a "brand name drug company" to mean the party that holds the approved application of a "brand name drug" or a party that is the owner of a patent for which information is submitted for such drug under subsection (b) or (c) of Section 505 of the FFDCA.

Section 1111(3) defines a "brand name drug" to mean a drug for which an application is approved under Section 505(c) of the FFDCA, including an application referred to in Section 505(b)(2) of the FFDCA.

2. Section 1112(b) Generic-Generic Agreements: Section 1112(b) requires a generic drug applicant that has submitted an ANDA containing a certification under Section 205(j)(2)(A)(vii)(IV) of the FDCA with respect to a listed drug and another generic drug applicant that has submitted an ANDA containing such a certification for the same listed drug that enter into an agreement related to the 180-day period referred to in Section 505(j)(5)(B)(iv) of the FDCA, to file the agreement with the Antitrust Agencies, subject to the requirements of Section 1112(c). Section 1112(b)(11) provides that “[t]he agreement shall be filed prior to the date of the first commercial marketing of either of the generic drugs for which such ANDAs were submitted.”

### *Filings of Agreements*

Section 1112(c) governs the filing of the agreements with the Antitrust Agencies:

1. Section 1112(c)(1) states that the parties subject to Section 1112(a) or (b) are **not** required to file an agreement that solely concerns
  - (A) purchase orders for raw materials;
  - (B) equipment and facility contracts;
  - (C) employment or consulting contracts; or
  - (D) packaging and labeling contracts.
2. Section 1112(c)(2) requires parties also to file the text of any agreements between the parties that are not described in Section 1112(a) or (b) and are contingent upon, provide a contingent condition for, or are otherwise related to an agreement that is required to be filed under Section 1112(a) or (b).
3. Section 1112(c)(3) requires that in the event that any agreement required to be filed under Section 1112(a) or (b) has not been reduced to text, each of the parties involved shall file written descriptions of such agreement that are sufficient to disclose all the terms and conditions of the agreement.

### *Filing Deadlines*

Section 1113 provides that “[a]ny filing required under Section 1112 shall be filed with [the Antitrust Authorities] not later than 10 business days after the date the agreements are executed.” If the agreement allows commercial marketing of a generic drug that is the subject of the ANDA within 10 business days of the agreement’s execution, the agreement shall be filed prior to the date of the first commercial marketing of the generic drug, as required by Sections 1112(a)(1) and 1112(b)(1).

### *Filing Copies and Addresses*

The parties required to file agreements pursuant to Sections 1112(a) and 1112(b) are requested to file two (2) copies of the agreement and cover sheet with the Federal Trade Commission and two (2) copies of the agreement and cover sheet with the Department of Justice

at the following addresses:

Premerger Notification Office  
Federal Trade Commission, Room 5301  
400 7<sup>th</sup> St., SW  
Washington, D.C. 20024

Director of Operations and Civil Enforcement  
Antitrust Division, Department of Justice  
950 Pennsylvania Avenue, N.W., Room 3335  
Washington, D.C. 20530  
(For FEDEX air bills to the Department of Justice, do not use the 20530 zip code, use zip code 20004)

*Enforcement*

Section 1115(a) of the Act provides that “[a]ny brand name drug company or generic drug applicant which fails to comply with any provision of this subtitle, the United States district court may order compliance, and may grant such other equitable relief as the court in its discretion determines necessary or appropriate, upon application of the Assistant Attorney General or the [Federal Trade] Commission.”

For Further Information: Contact Theresa Kingsberry, Federal Trade Commission (202) 326-3786 or Elaine Gibbs, Department of Justice (202) 514-2558.